Showing 2241-2250 of 2652 results for "".
- Samsara Vision: Patients Blinded by Macular Degeneration May Benefit From Implant Technologyhttps://modernod.com/news/samsara-vision-reports-that-patients-blinded-by-macular-degeneration-benefit-from-milestone-in-implant-technology/2479242/Samsara Vision announced the first successful clinical cases in Europe using their smaller-incision new-generation implantable miniature telescope (SING IMT) for people living with late-stage age-related macular degeneration (AMD). The SING IMT, performed with the TSert delivery system, was succe
- CooperVision DreamLite Ortho-K Lenses Gain European Approval for Slowing Progression of Myopiahttps://modernod.com/news/coopervision-dreamlite-ortho-k-lenses-gain-european-approval-for-slowing-progression-of-myopia/2479240/CooperVision Specialty EyeCare’s Procornea DreamLite night lenses have received European approval for slowing the progression of myopia in children and young adults. The orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Parago
- Okayama University Research: High Levels of Television Exposure Affect Visual Acuity in Childrenhttps://modernod.com/news/okayama-university-research-high-levels-of-television-exposure-affect-visual-acuity-in-children/2479236/In a study reported in the Japanese Journal of Ophthalmology, researchers from Okayama University show that long hours in front of the television in children under 3 years of age lead to increased eyesight concerns during later years. It is ingrained in parents to curtail the hours
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- Schwind ATOS Receives “Winner” Award at the German Innovation Awards 2021https://modernod.com/news/schwind-atos-receives-winner-award-at-the-german-innovation-awards-2021/2479226/Schwind eye-tech-solutions has received an award for the youngest member of its laser product familiy: the Schwind ATOS femtosecond laser. Schwind recently received the prestigious “Winner” award at the Ge
- Rayner Receives FDA Approval for RayOne Spheric Monofocal IOLhttps://modernod.com/news/rayner-receives-fda-approval-for-rayone-spheric-monofocal-iol/2479221/Rayner has received FDA approval for the RayOne Spheric fully-preloaded monofocal IOL. The approval marks Rayner’s third FDA approval in under 3 years within its RayOne preloaded IOL portfolio. RayOne Spheric joins RayOne Aspheric (FDA approved December 2018) and RayOne EMV, a new non-diffractive
- SIFI and Bausch Health Russia Announce Strategic Commercial Partnershiphttps://modernod.com/news/sifi-and-bausch-health-russia-announce-strategic-commercial-partnership/2479213/Italian ophthalmic company SIFI announced it has entered into a strategic multi-year agreement with Bausch Health Russia to market its products treating ophthalmic disorders in Russia. Terms of the deal were not disclosed. Initial sales are expected in 2021, marketing 5 SIFI product
- Oxurion Appoints Tom Graney, CFA, as Chief Executive Officerhttps://modernod.com/news/oxurion-appoints-tom-graney-cfa-as-chief-executive-officer/2479215/Oxurion NV announced in a planned succession, the promotion of Tom Graney, CFA, from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Patrik De Haes, MD, who after 14 years as CEO has decided to move away from day-to-day management
- First Pediatric Patient with Rare Genetic Eye Disease Dosed in Clinical Trialhttps://modernod.com/news/first-pediatric-patient-with-rare-genetic-eye-disease-dosed-in-clinical-trial/2479207/ProQR Therapeutics has announced the first pediatric clinical trial participant has been treated in its new clinical trial named Brighten of the experimental RNA therapy sepofarsen. Brighten is a clinical study for children under 8 years old with Leber congenital amaurosis (LCA) d
- New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced AMD Progressionhttps://modernod.com/news/new-national-eye-institute-data-shows-areds2-nutrient-formula-continues-to-reduce-the-risk-of-moderate-to-advanced-amd-progression/2479193/Bausch + Lomb announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help